Corstasis Therapeutics to Present Pivotal Trial Data on Novel Bumetanide Nasal Spray at American Heart Association Scientific Sessions 2024

Contributed by: Business Wire

Logo

Business Wire logo

Tags

Health
Hospitals
Other Health
General Health
Clinical Trials
Pharmaceutical
Biotechnology
Corstasis Therapeutics Inc.

More Like This

Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress

Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

PR Newswire associated0

Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis

Business Wire logo

Zambon Announces Publication of Phase 3 PROMIS I and II Study Results in The Lancet Respiratory Medicine Showing Efficacy Results of CMS I-neb in Patients with Non-Cystic Fibrosis Bronchiectasis Colonized with P. aeruginosa

Calliditas initiates clinical study to evaluate setanaxib in Alport Syndrome

Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress